POSTMARKETING SURVEILLANCE RATES OF UVEITIS AND SCLERITIS WITH BISPHOSPHONATES AMONG A NATIONAL VETERAN COHORT
- 1 June 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Retina
- Vol. 28 (6), 889-893
- https://doi.org/10.1097/iae.0b013e31816576ef
Abstract
Uveitis and scleritis are the most serious ocular side effects of bisphosphonate therapy. The purpose of this study was to determine the 6-month rates of uveitis/scleritis following dispensing of bisphosphonates in a large veteran cohort. Two national databases (clinical and pharmacy) for fiscal year (FY) 2006 were linked to identify new diagnoses of uveitis/scleritis following the initial dispensing of bisphosphonate drugs. New diagnoses in FY 2006 were identified using International Classification of Diseases, Version 9, Clinical Modification (ICD-9-CM), in a cohort of veterans without a previous diagnosis of uveitis or scleritis using a look-back period to FY 2005. The new diagnoses were temporally aligned with initial dispensing of bisphosphonates and the rates of new cases were calculated for 1-month and 6-month time intervals. There were 7.9 new cases of uveitis/scleritis per 10,000 individuals with a newly dispensed bisphosphonate that occurred within 180 days. The relative risk of uveitis/scleritis for 6 months was 1.23 (95% confidence interval: 0.85-1.79) compared to veterans not exposed to the medications. The rates of uveitis/scleritis did not differ significantly based on route of administration (oral or parenteral) or after age adjustment. Just over a third of the diagnoses were scleritis. Nearly 43% of patients with uveitis/scleritis after bisphosphonate use had a systemic diagnosis commonly associated with inflammation of the uveal tract or sclera. The 30-day and 6-month rates of uveitis/scleritis following the dispensing of a bisphosphonate drug are low and do not differ significantly from rates recorded for veterans not dispensed these drugs.Keywords
This publication has 9 references indexed in Scilit:
- Scleritis Complicating Zoledronic Acid InfusionClinical Lymphoma Myeloma and Leukemia, 2006
- Ophthalmological Events in Patients Receiving RisedronateDrug Safety, 2006
- Bisphosphonate-associated Scleritis: A Case Report and ReviewSouthern Medical Journal, 2005
- Bisphosphonates and Ocular InflammationThe New England Journal of Medicine, 2003
- Scleritis and other ocular side effects associated with pamidronate disodiumAmerican Journal of Ophthalmology, 2003
- Ocular side effects associated with bisphosphonatesDrugs of Today, 2003
- Drug-Induced UveitisSurvey of Ophthalmology, 1998
- Pamidronate Disodium and Possible Ocular Adverse Drug ReactionsAmerican Journal of Ophthalmology, 1994
- Bisphosphonates and iritisThe Lancet, 1993